Evidence map›Paper›PMID 18184901›Full record

Trial reportDiabetes care2008

Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients.

Kwang Kon Koh, Michael J Quon, Seung Hwan Han, Yonghee Lee, Jeong Yeal Ahn, Soo Jin Kim, Yesl Koh, Eak Kyun Shin

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 4 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Choosing statins: a review to guide clinical practice.Archives of endocrinology and metabolism · 2021
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Mechanisms of statin-induced new-onset diabetes.Journal of cellular physiology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Kwang Kon KohDivison of Cardiology, Gil Medical Center, Gachon University, Incheon, Korea. kwangk@gilhospital.com
Michael J Quon
Seung Hwan Han
Yonghee Lee
Jeong Yeal Ahn
Soo Jin Kim
Yesl Koh
Eak Kyun Shin
Gachon University Gil Medical Center · KREwha Womans University · KRNational Center for Complementary and Integrative Health · USNorthwestern University · US

Funding

Insulin Stimulated Production Of Nitric Oxide In Vascular EndotheliumZ01AT000001 · NCCIH · NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH · PI QUON, MICHAEL J. · 2002 to 2008
$2.4M
Intramural NIH HHS Z01 AT000001
6 · The paper itself

Abstract

objectiveWe hypothesized that simvastatin may reduce adiponectin levels and insulin sensitivity in hypercholesterolemic patients. RESEARCH DESIGN AND

methodsThis was a randomized, double-blind, placebo-controlled, parallel study. Age, sex, and BMI were matched. Thirty-two patients were given placebo, and 30, 32, 31, and 31 patients were given daily 10, 20, 40, and 80 mg simvastatin, respectively, during a 2-month treatment period.

resultsSimvastatin doses of 10, 20, 40, and 80 mg significantly reduced total cholesterol (mean changes 27, 25, 37, and 38%), LDL cholesterol (39, 38, 52, and 54%), and apolipoprotein B levels (24, 30, 36, and 42%) and improved flow-mediated dilation (FMD) (68, 40, 49, and 63%) after 2 months of therapy compared with baseline (P < 0.001 by paired t test) or compared with placebo (P < 0.001 by ANOVA). Simvastatin doses of 10, 20, 40, and 80 mg significantly decreased plasma adiponectin levels (4, 12, 5, and 10%) and insulin sensitivity (determined by the Quantitative Insulin-Sensitivity Check Index [QUICKI]) (5, 8, 6, and 6%) compared with baseline (P < 0.05 by paired t test) or compared with placebo (P = 0.011 for adiponectin and P = 0.034 for QUICKI by ANOVA). However, the magnitudes of these percent changes (FMD, adiponectin, and QUICKI) were not significantly different among four different doses of simvastatin despite dose-dependent changes in the reduction of apolipoprotein B levels.

conclusionsSimvastatin significantly improved endothelium-dependent dilation, but reduced adiponectin levels and insulin sensitivity in hypercholesterolemic patients independent of dose and the extent of apolipoprotein B reduction.

Indexed as

Insulin ResistanceAdiponectinApolipoproteins BBlood Flow VelocityBody Mass IndexCholesterol, LDLC-Reactive ProteinDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMalePlacebosSimvastatinAdiponectinApolipoproteins BCholesterol, LDLC-Reactive ProteinHydroxymethylglutaryl-CoA Reductase InhibitorsPlacebosSimvastatin

Identifiers

PMID18184901
PMCPMC2950311
OpenAlexW2164781406

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.